BACKGROUND: To evaluate whether feedback of genetic information regarding an L-myc polymorphism, identified as impacting on tobacco-related cancer risk, has an influence on smoking cessation, an intervention study was conducted. METHODS: We recruited smokers from first-visit outpatients at Aichi Cancer Center Hospital. Six hundred and seventeen participated and were allocated into two groups: the biomarker feedback group (BF) and the follow-up smoking status group (FS). The subjects were asked for their smoking status at enrolment and at 3- and 9-month follow-ups. BF subjects were notified about their L-myc genotype. RESULTS: The smoking cessation rate at 9-month follow-up was essentially the same for both BF and FS cases, at 18.8% and 17.0%, respectively (P = 0.798). However, a difference in the rate was evident with non-cancer subjects (12.7% and 8.4%, respectively, P = 0.237), especially in females (15.0% and 4.2%, respectively, P = 0.024). The non-cancer subjects informed of their genotype were more likely to quit smoking than the FS patients; particularly in those having a risky genotype, this was significant (odds ratio: 2.87, P = 0.003). Again it was most prominent in females. CONCLUSION: Feedback regarding an L-myc polymorphism did not impact on smoking cessation overall but appeared to benefit smokers without cancer. In addition, gender could affect the response to the feedback.
BACKGROUND: To evaluate whether feedback of genetic information regarding an L-myc polymorphism, identified as impacting on tobacco-related cancer risk, has an influence on smoking cessation, an intervention study was conducted. METHODS: We recruited smokers from first-visit outpatients at Aichi Cancer Center Hospital. Six hundred and seventeen participated and were allocated into two groups: the biomarker feedback group (BF) and the follow-up smoking status group (FS). The subjects were asked for their smoking status at enrolment and at 3- and 9-month follow-ups. BF subjects were notified about their L-myc genotype. RESULTS: The smoking cessation rate at 9-month follow-up was essentially the same for both BF and FS cases, at 18.8% and 17.0%, respectively (P = 0.798). However, a difference in the rate was evident with non-cancer subjects (12.7% and 8.4%, respectively, P = 0.237), especially in females (15.0% and 4.2%, respectively, P = 0.024). The non-cancer subjects informed of their genotype were more likely to quit smoking than the FS patients; particularly in those having a risky genotype, this was significant (odds ratio: 2.87, P = 0.003). Again it was most prominent in females. CONCLUSION: Feedback regarding an L-myc polymorphism did not impact on smoking cessation overall but appeared to benefit smokers without cancer. In addition, gender could affect the response to the feedback.
Authors: Saskia C Sanderson; Suzanne C O'Neill; Della Brown White; Gerold Bepler; Lori Bastian; Isaac M Lipkus; Colleen M McBride Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06-30 Impact factor: 4.254
Authors: Xinyu Tang; Charlotte A Hobbs; Mario A Cleves; Stephen W Erickson; Stewart L MacLeod; Sadia Malik Journal: Birth Defects Res A Clin Mol Teratol Date: 2015-06-02
Authors: S C Sanderson; C M McBride; S C O'Neill; S Docherty; J Shepperd; I M Lipkus Journal: Public Health Genomics Date: 2014-02-19 Impact factor: 2.000
Authors: Joanne Soo-Min Kim; Peter C Coyte; Michelle Cotterchio; Louise A Keogh; Louisa B Flander; Clara Gaff; Audrey Laporte Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-15 Impact factor: 4.254
Authors: Kristi D Graves; Kara-Grace Leventhal; Rachel Nusbaum; Yasmin Salehizadeh; Gillian W Hooker; Beth N Peshkin; Morgan Butrick; William Tuong; Jeena Mathew; David Goerlitz; Mary B Fishman; Peter G Shields; Marc D Schwartz Journal: Genomics Date: 2013-04-11 Impact factor: 5.736